STAAR SURGICAL CO

STAAR SURGICAL COSTAAEarnings & Financial Report

Nasdaq · Health Care · Ophthalmic Goods

STAAR Surgical Co is a global ophthalmic medical device firm. It designs, makes and sells implantable collamer lenses (ICLs) for minimally invasive vision correction, plus supporting surgical products for ophthalmologists across North America, Europe, Asia Pacific and other key regional markets.

Revenue

$99.0M

Gross Profit

$78.4M

Operating Profit

$11.9M

Net Profit

$7.4M

Gross Margin

79.2%

Operating Margin

12.0%

Net Margin

7.5%

YoY Growth

7.3%

EPS

$0.15

STAAR SURGICAL CO Q2 FY2024 Financial Summary

STAAR SURGICAL CO reported revenue of $99.0M (up 7.3% YoY) for Q2 FY2024, with a net profit of $7.4M (up 21.7% YoY) (7.5% margin). Cost of goods sold was $20.6M, operating expenses totaled $66.5M.

Key Financial Metrics

Total Revenue$99.0M
Net Profit$7.4M
Gross Margin79.2%
Operating Margin12.0%
Report PeriodQ2 FY2024

Revenue Breakdown

STAAR SURGICAL CO Q2 FY2024 revenue of $99.0M breaks down across 3 segments, led by Other at $54.7M (55.2% of total).

SegmentRevenue% of Total
Other$54.7M55.2%
Non Consignment Sales$37.5M37.9%
Consignment Sales$6.8M6.9%

STAAR SURGICAL CO Revenue by Segment — Quarterly Trend

STAAR SURGICAL CO revenue by segment across the last 4 reported quarters, showing how each business line (such as Other and Non Consignment Sales) has evolved quarter over quarter.

SegmentQ4 FY2024Q3 FY2024Q2 FY2024Q1 FY2024
Other$25.6M$54.7M$23.0M
Non Consignment Sales$63.0M$37.5M
Consignment Sales$6.8M$4.7M

STAAR SURGICAL CO Annual Revenue by Year

STAAR SURGICAL CO annual revenue history includes year-by-year totals (for example, 2024 revenue was $313.9M).

YearAnnual Revenue
2024$313.9M
2023$322.4M
2022$239.4M
2021$124.7M

STAAR SURGICAL CO Quarterly Revenue & Net Profit History

STAAR SURGICAL CO results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q4 FY2024$49.0M-35.8%$-34.2M-69.9%
Q3 FY2024$88.6M+10.3%$10.0M11.3%
Q2 FY2024$99.0M+7.3%$7.4M7.5%
Q1 FY2024$77.4M+5.2%$-3.3M-4.3%
Q4 FY2023$76.3M+299.4%$7.8M10.2%
Q3 FY2023$80.3M+5.6%$4.8M6.0%
Q2 FY2023$92.3M+13.8%$6.1M6.6%
Q1 FY2023$73.5M+16.3%$2.7M3.7%

Income Statement

Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024
Revenue$73.5M$92.3M$80.3M$76.3M$77.4M$99.0M$88.6M$49.0M
YoY Growth16.3%13.8%5.6%299.4%5.2%7.3%10.3%-35.8%

Balance Sheet

Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024
Assets$418.9M$440.7M$471.5M$488.7M$492.5M$512.7M$537.6M$509.5M
Liabilities$80.0M$87.0M$92.9M$102.7M$99.7M$103.6M$109.5M$112.2M
Equity$342.8M$357.6M$378.6M$386.0M$392.8M$409.1M$428.1M$397.3M

Cash Flow

Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024
Operating CF$-5.1M$-6.3M$-6.0M$32.0M$21.7M$-10.4M$3.8M$642000